[go: up one dir, main page]

HK1258098A1 - 治療癌症的方法 - Google Patents

治療癌症的方法 Download PDF

Info

Publication number
HK1258098A1
HK1258098A1 HK19100681.3A HK19100681A HK1258098A1 HK 1258098 A1 HK1258098 A1 HK 1258098A1 HK 19100681 A HK19100681 A HK 19100681A HK 1258098 A1 HK1258098 A1 HK 1258098A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating cancer
melanomas
compositions
disclosed
Prior art date
Application number
HK19100681.3A
Other languages
English (en)
Inventor
Garrett Michael FRAMPTON
Roman YELENSKY
James Xin SUN
Douglas Buckner JOHNSON
Christine Marie LOVLY
Jeffrey Alan SOSMAN
David Fabrizio
Philip J. Stephens
Vincent A. Miller
Original Assignee
Foundation Medicine, Inc.
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foundation Medicine, Inc., Vanderbilt University filed Critical Foundation Medicine, Inc.
Publication of HK1258098A1 publication Critical patent/HK1258098A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/15—Correlation function computation including computation of convolution operations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Databases & Information Systems (AREA)
  • Biomedical Technology (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mathematical Analysis (AREA)
  • Pure & Applied Mathematics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Mathematical Physics (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
HK19100681.3A 2016-02-29 2017-02-27 治療癌症的方法 HK1258098A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301510P 2016-02-29 2016-02-29
US62/301,510 2016-02-29
PCT/US2017/019733 WO2017151517A1 (en) 2016-02-29 2017-02-27 Methods of treating cancer

Publications (1)

Publication Number Publication Date
HK1258098A1 true HK1258098A1 (zh) 2019-11-01

Family

ID=59744346

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100681.3A HK1258098A1 (zh) 2016-02-29 2017-02-27 治療癌症的方法

Country Status (8)

Country Link
US (2) US11725247B2 (zh)
EP (1) EP3423488A4 (zh)
JP (3) JP2019509282A (zh)
CN (1) CN109476731A (zh)
AU (1) AU2017225869A1 (zh)
CA (1) CA3015913A1 (zh)
HK (1) HK1258098A1 (zh)
WO (1) WO2017151517A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
MX2018010361A (es) 2016-02-29 2019-07-08 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
JP2019509282A (ja) 2016-02-29 2019-04-04 ファウンデーション・メディシン・インコーポレイテッド 癌の治療方法
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
KR102775647B1 (ko) * 2017-03-31 2025-03-06 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
KR102145417B1 (ko) * 2017-05-24 2020-08-19 지니너스 주식회사 무세포 핵산으로부터 수득된 서열 분석 데이터에 대한 배경 대립인자의 빈도 분포를 생성하는 방법 및 이를 이용하여 무세포 핵산으로부터 변이를 검출하는 방법
IL271888B2 (en) 2017-07-21 2024-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer
US11640848B2 (en) * 2017-09-20 2023-05-02 Regeneron Pharmaceuticals, Inc. Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
EP3687574A2 (en) * 2017-09-25 2020-08-05 Memorial Sloan-Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
WO2019063802A1 (en) * 2017-09-29 2019-04-04 Boehringer Ingelheim International Gmbh ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1
CN111247169A (zh) 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
WO2019090156A1 (en) * 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
CA3099057C (en) * 2018-05-03 2023-09-19 Aarthi Balasubramanyam Surrogate marker and method for tumor mutation burden measurement
KR20210038577A (ko) 2018-07-23 2021-04-07 가던트 헬쓰, 인크. 종양 분율 및 커버리지에 의해 종양 돌연변이 부담을 조정하기 위한 방법 및 시스템
EP3844761A1 (en) 2018-08-31 2021-07-07 Guardant Health, Inc. Microsatellite instability detection in cell-free dna
US20210348238A1 (en) * 2018-10-16 2021-11-11 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
EP3880246A4 (en) * 2018-11-15 2022-08-10 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
CN109288850B (zh) * 2018-11-21 2019-10-29 浙江大学 熊脱氧胆酸或其药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
EP3899951A1 (en) * 2018-12-23 2021-10-27 F. Hoffmann-La Roche AG Tumor classification based on predicted tumor mutational burden
GB201904555D0 (en) * 2019-04-01 2019-05-15 Univ Manchester Biomarkers and uses thereof
CA3142400A1 (en) * 2019-07-11 2021-01-14 Biocartis Nv Method and genetic signature for detecting increased tumor mutational burden
MX2023002123A (es) 2020-08-26 2023-03-15 Regeneron Pharma Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1.
WO2022125470A1 (en) * 2020-12-07 2022-06-16 Foundation Medicine, Inc. Comprehensive genomic profiling (cgp) of metastatic invasive lobular carcinomas reveals heterogeneity
CN116981478A (zh) * 2021-03-19 2023-10-31 上海君实生物医药科技股份有限公司 抗pd-1抗体在制备治疗尿路上皮癌的药物中的用途
EP4349983A4 (en) * 2021-05-27 2025-06-18 National Institute Of Advanced Industrial Science and Technology Genome editing method
WO2023284260A1 (zh) * 2021-07-12 2023-01-19 广州燃石医学检验所有限公司 基于血液测序的肿瘤内异质性的评估方法及其用于预测免疫疗法的应答
CN115925881B (zh) * 2022-08-26 2023-07-11 中国药科大学 一种抑制set蛋白核质穿梭的多肽及其应用
WO2024089417A1 (en) * 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6277569B1 (en) 1990-09-20 2001-08-21 Vysis, Inc. Methods for multiple direct label probe detection of multiple chromosomes or regions thereof by in situ hybridization
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0679196B1 (en) 1993-01-07 2004-05-26 Sequenom, Inc. Dna sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
ATE220114T1 (de) 1993-03-19 2002-07-15 Sequenom Inc Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
US6261775B1 (en) 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7556944B2 (en) 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
DE60328214D1 (de) 2002-08-12 2009-08-13 New England Biolabs Inc Verfahren und zusammensetzungen in verbindung mit gen-silencing
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
ME02260B (me) 2005-07-01 2016-02-29 Medarex Inc Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
EP2245198A1 (en) 2008-02-04 2010-11-03 Massachusetts Institute of Technology Selection of nucleic acids by solution hybridization to oligonucleotide baits
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2659003A4 (en) 2010-12-30 2014-05-21 Foundation Medicine Inc OPTIMIZING MULTIGENANALYSES OF TUMOR SAMPLES
US9157125B2 (en) * 2011-02-02 2015-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services GRIN2A mutations and use thereof for the diagnosis of melanoma
AU2012335955A1 (en) 2011-11-07 2014-07-03 QIAGEN Redwood City, Inc. Methods and systems for identification of causal genomic variants
US20140287937A1 (en) 2013-02-21 2014-09-25 Toma Biosciences, Inc. Methods for assessing cancer
GB2526736A (en) * 2013-02-21 2015-12-02 Toma Biosciences Inc Methods, compositions, and kits for nucleic acid analysis
NZ712314A (en) 2013-03-15 2021-07-30 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EP4253558B1 (en) 2013-03-15 2025-07-02 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
AU2014262481A1 (en) 2013-05-10 2015-11-26 Foundation Medicine, Inc. Analysis of genetic variants
EP3083687A2 (en) 2013-12-17 2016-10-26 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
PE20161344A1 (es) * 2014-01-02 2016-12-23 Memorial Sloan Kettering Cancer Center Determinantes de respuesta del cancer a la inmunoterapia
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2015164862A1 (en) 2014-04-25 2015-10-29 Memorial Sloan-Kettering Cancer Center Treatment of h-ras-driven tumors
ES2916923T3 (es) 2014-07-11 2022-07-06 Ventana Med Syst Inc Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
WO2016018481A2 (en) 2014-07-28 2016-02-04 The Regents Of The University Of California Network based stratification of tumor mutations
SG11201703541PA (en) 2014-11-13 2017-05-30 Univ Johns Hopkins Checkpoint blockade and microsatellite instability
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
JP2018501218A (ja) 2014-12-02 2018-01-18 セルジーン コーポレイション 併用療法
EP3265079A4 (en) 2015-03-03 2019-01-02 Caris MPI, Inc. Molecular profiling for cancer
WO2017040960A1 (en) 2015-09-04 2017-03-09 The Brigham And Women's Hospital, Inc. Programmed cell death 1 (pd-1 ) inhibitor therapy for patients with pd-1 -expressing cancers
JP2019509282A (ja) 2016-02-29 2019-04-04 ファウンデーション・メディシン・インコーポレイテッド 癌の治療方法
MX2018010361A (es) 2016-02-29 2019-07-08 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
CN109196359B (zh) 2016-02-29 2022-04-12 基础医疗股份有限公司 用于评估肿瘤突变负荷的方法和系统
ES3019936T3 (en) 2016-03-22 2025-05-21 Myriad Womens Health Inc Combinatorial dna screening
JP7050702B2 (ja) 2016-07-08 2022-04-08 ジェネンテック， インコーポレイテッド Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
EP3601600A2 (en) 2017-03-31 2020-02-05 MedImmune, LLC Tumor burden as measured by cell free dna
IL271888B2 (en) 2017-07-21 2024-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer
ES3016786T3 (en) 2018-08-01 2025-05-09 Genentech Inc Prediction and characterization of dlbcl cell of origin subtypes

Also Published As

Publication number Publication date
CN109476731A (zh) 2019-03-15
US20240392378A1 (en) 2024-11-28
AU2017225869A1 (en) 2018-09-06
CA3015913A1 (en) 2017-09-08
EP3423488A4 (en) 2019-11-06
WO2017151517A1 (en) 2017-09-08
US20190085403A1 (en) 2019-03-21
JP2020100641A (ja) 2020-07-02
JP2019509282A (ja) 2019-04-04
US11725247B2 (en) 2023-08-15
JP2023100899A (ja) 2023-07-19
EP3423488A1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
HK1258098A1 (zh) 治療癌症的方法
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
EP3532464A4 (en) COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER
IL267247B (en) Compositions and methods for treating cancer
EP3368559A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3458158A4 (en) COMPOSITIONS AND METHODS FOR TREATING ECZEMA
EP3258966A4 (en) Methods, compositions, and kits for treatment of cancer
EP3320093A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION AND TREATMENT OF CANCER USING SLNCR ISOFORMS
IL269157A (en) Preparations and methods for the treatment of cancer
IL268163A (en) Methods, compositions, and kits for treatment of cancer
EP3638293A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
EP3688023A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3429613A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3714043A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
IL272782A (en) Preparations and methods for the treatment of cancer
EP3773585A4 (en) Compositions and methods for treating cancer
EP3723765A4 (en) CANCER TREATMENT METHODS
EP3877514A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3268028A4 (en) Compositions and methods for treating cancer
EP3426299A4 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF TUMORS
EP3592357A4 (en) METHOD OF TREATMENT OF CANCER
HK40093247A (zh) 治療癌症的組合物及方法
HK40091841A (zh) 用於治療癌症的方法和組合物
HK40091839A (zh) 用於治療癌症的方法和組合物